Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF02220621PMID 1451725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.

  2015cited by this paper
• Leukotriene (LT) D4 Is Involved in Antigen‐Induced Asthma: a Study with the LTD4 Receptor Antagonist, MK‐571

  1991cited by this paper
• Stereoselective determination of R(-)- and S(+)-MK-571, a leukotriene D4 antagonist, in human plasma by chiral high-performance liquid chromatography.

  1991cited by this paper
• MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

  1991cited by this paper
• Interspecies differences in stereoselective protein binding and clearance of MK-571.

  1990cited by this paper
• Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist.

  1989cited by this paper
• Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls.

  1986cited by this paper
• The effect of inhaled leukotriene D4 in humans.

  1985cited by this paper
• Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human Skin

  1983cited by this paper
• Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin.

  1983cited by this paper
• Leukotrienes are potent constrictors of human bronchi

  1980cited by this paper

• The multidrug resistance protein inhibitor, MK571 inhibits the hypercontractility state in prostate from obese mice

  2025influential citation
• MRP1-Dependent Extracellular Release of Glutathione Induces Cardiomyocyte Ferroptosis After Ischemia-Reperfusion

  2023cites this paper
• Overexpression of Cyclic Adenosine Monophosphate Effluent Protein MRP4 Induces an Altered Response to &bgr;-Adrenergic Stimulation in the Senescent Rat Heart

  2015cites this paper
• A 2-amino quinoline, 5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid, interacts with PfMDR1 and inhibits its drug transport in Plasmodium falciparum.

  2014cites this paper
• Discovery and Development of Montelukast (Singulair

  2012cites this paper
• Primeras administraciones de un nuevo antileucotrieno en humanos: seguridad y farmacocinética. Papel del modelado poblacional en el desarrollo clínico de nuevos compuestos

  2007cites this paper
• Dose-dependent kinetics of the enantiomers of MK-571, an LTD4-receptor antagonist

  2005cites this paper
• Identification of multidrug resistance‐associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine

  2004cites this paper
• The blood-brain barrier and oncology: new insights into function and modulation.

  2000cites this paper
• Biology and pathophysiology of leukotrienes.

  1996cites this paper
• Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors.

  1996cites this paper
• Pharmacokinetics and pharmacodynamics of multiple oral doses of MK‐0591, a 5‐lipoxygenase—activating protein inhibitor

  1994cites this paper
• Biochemical activity, pharmacokinetics, and tolerability of MK‐886, a leukotriene biosynthesis inhibitor, in humans

  1993cites this paper